OXT-328 | CAS#unknown | NSAID compound

MedKoo Cat#: 465692 | Name: OXT-328

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OXT-328 is phospho-modified NSAID compound.

Chemical Structure

OXT-328

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465692

Name: OXT-328

CAS#: unknown

Chemical Formula: C28H34FO7PS

Exact Mass: 564.1747

Molecular Weight: 564.61

Elemental Analysis: C, 59.57; H, 6.07; F, 3.36; O, 19.84; P, 5.49; S, 5.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

OXT-328; OXT328; OXT 328; Phospho-Sulindae; Phospho Sulindae; Phosphosulindae;

IUPAC/Chemical Name

4-((diethoxyphosphoryl)oxy)butyl (Z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate

InChi Key

DTBSJPFGPBZPHE-UQQQWYQISA-N

InChi Code

InChI=1S/C28H34FO7PS/c1-5-34-37(31,35-6-2)36-16-8-7-15-33-28(30)19-26-20(3)25(24-14-11-22(29)18-27(24)26)17-21-9-12-23(13-10-21)38(4)32/h9-14,17-18H,5-8,15-16,19H2,1-4H3/b25-17-

SMILES Code

O=C(OCCCCOP(OCC)(OCC)=O)CC1=C(C)/C(C2=CC=C(F)C=C21)=C/C3=CC=C(S(C)=O)C=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 564.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Huang W, Wen Z, Saglam MS, Huang L, Honkanen RA, Rigas B. Phospho-Sulindac (OXT-328) Inhibits Dry Eye Disease in Rabbits: A Dose-, Formulation- and Structure-Dependent Effect. J Ocul Pharmacol Ther. 2021 Jul-Aug;37(6):321-330. doi: 10.1089/jop.2019.0025. Epub 2021 Jun 21. PMID: 34152861. 2: Wen Z, Muratomi N, Huang W, Huang L, Ren J, Yang J, Persaud Y, Loloi J, Mallangada N, Kung P, Honkanen R, Rigas B. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery. Int J Pharm. 2019 Feb 25;557:273-279. doi: 10.1016/j.ijpharm.2018.12.057. Epub 2018 Dec 28. PMID: 30597269. 3: Honkanen RA, Huang L, Xie G, Rigas B. Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. Transl Res. 2018 Aug;198:58-72. doi: 10.1016/j.trsl.2018.04.002. Epub 2018 Apr 10. PMID: 29702077. 4: Wong CC, Cheng KW, Papayannis I, Mattheolabakis G, Huang L, Xie G, Ouyang N, Rigas B. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharm Res. 2015 May;32(5):1663-75. doi: 10.1007/s11095-014-1565-2. Epub 2014 Nov 13. PMID: 25392229; PMCID: PMC4382427. 5: Murray OT, Wong CC, Vrankova K, Rigas B. Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. Int J Oncol. 2014 Feb;44(2):521-9. doi: 10.3892/ijo.2013.2190. Epub 2013 Nov 27. PMID: 24284479; PMCID: PMC3898803. 6: Mattheolabakis G, Mackenzie GG, Huang L, Ouyang N, Cheng KW, Rigas B. Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats. Pharm Res. 2013 Jun;30(6):1471-82. doi: 10.1007/s11095-012-0953-8. Epub 2013 Mar 13. PMID: 23483440; PMCID: PMC4395004. 7: Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, Rigas B. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol. 2012 Oct;41(4):1199-203. doi: 10.3892/ijo.2012.1577. Epub 2012 Jul 27. PMID: 22842609; PMCID: PMC3583614. 8: Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, Vrankova K, Constantinides PP, Rigas B. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharm Res. 2012 Nov;29(11):3090-101. doi: 10.1007/s11095-012-0801-x. Epub 2012 Jun 22. PMID: 22723123; PMCID: PMC3584452. 9: Zhu C, Cheng KW, Ouyang N, Huang L, Sun Y, Constantinides P, Rigas B. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells. 2012 Oct;30(10):2065-75. doi: 10.1002/stem.1139. PMID: 22653497; PMCID: PMC3621090. 10: Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B. Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety. Br J Pharmacol. 2012 Sep;167(1):222-32. doi: 10.1111/j.1476-5381.2012.01982.x. PMID: 22489789; PMCID: PMC3448925. 11: Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, Rigas B. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther. 2012 Feb;340(2):422-32. doi: 10.1124/jpet.111.188508. Epub 2011 Nov 15. PMID: 22085648; PMCID: PMC3263964. 12: Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L, Rigas B. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol. 2012 Apr;165(7):2152-66. doi: 10.1111/j.1476-5381.2011.01705.x. PMID: 21955327; PMCID: PMC3413853. 13: Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila). 2011 Jul;4(7):1052-60. doi: 10.1158/1940-6207.CAPR-11-0067. Epub 2011 Apr 4. PMID: 21464038; PMCID: PMC3131469. 14: Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, Rigas B. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol. 2011 Apr;162(7):1521-33. doi: 10.1111/j.1476-5381.2010.01162.x. PMID: 21175575; PMCID: PMC3057290. 15: Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology. 2010 Oct;139(4):1320-32. doi: 10.1053/j.gastro.2010.06.044. Epub 2010 Jun 20. Erratum in: Gastroenterology. 2012 Mar;142(3):676. PMID: 20600034; PMCID: PMC2949489.